Video
JPM Week 2024: Addressing the Latest Market Drivers and Trends for Biologics and Sterile Injectables
Summary: In a recent presentation during the 2024 JP Morgan Healthcare Conference, Catalent’s Group President of Biologics Dave McErlane addresses the latest market drivers for Biologics and Sterile Injectables.
View Now
White Papers
Leveraging Post-Translational Modifications & Biofunctional Assays for the Characterization of Charged Variants
In this article, Catalent explores protein variants, focusing on charged variants, by outlining their impact on protein-based drugs, and explain how specific characterization techniques can be used to determine product safety and efficacy.
View Now
Webinars
Automating Cell Based Assays, Reducing Variability and Time to Results
In this presentation, the development of a cell-based potency assay on an automated platform is discussed.
View Now
Offering Fact Sheet
Biologics Analytical Services - Cell & Gene Therapy
Summary: Catalent Biologics provides characterization and GMP support for a full spectrum of biologics including advanced modalities, such as cell and gene therapies, mRNA, and antibody-drug conjugates (ADCs).
View Now
Offering Fact Sheet
Biologics Analytical Services - Bioassays
Summary: Catalent offers a comprehensive suite of bioassay development services for traditional biologics and advanced therapies, such as antibody-drug conjugates (ADCs), cell and gene therapies, and mRNA vaccines.
View Now
White Papers
Leveraging Novel Analytical Approaches for Advanced Therapies
Catalent has developed a relative potency bioassay using quantitative polymerase chain reaction (qPCR) to assess relative transcription activity in cells treated with ligands or transgenic vectors. The assay platform can be used to qualify a repeatable, accurate, linear, and specific bioassay for assessing relative potency for CGTs, mRNA- and other nucleic acid-based therapies.
View Now
Offering Fact Sheet
Biologics Analytical Services - ADC
Catalent Biologics provides characterization and GMP support for a full spectrum of biologics including advanced modalities, such as cell and gene therapies, mRNA, and antibody-drug conjugates (ADCs). Our comprehensive, standalone analytical services for ADCs are conducted by our in-house experts and tailored to meet your needs, regardless of scope or phase.
View Now
Webinars
Leveraging Post-Translational Modifications & Bio-Functional Assays for Characterization of Charged Variants
During this webinar, Catalent experts will discuss challenges associated with charged variants of biotherapeutic products, including monoclonal antibodies and fusion proteins.
View Now
Article
The New Normal: How the Supply Chain has Been Impacted by COVID-19
Summary: Supply chains have come under intense pressure, and companies have had to adapt to this “new normal” to avoid delays. During this Q&A, Catalent discusses....
View Now
Webinars
Women in BioPharma Awards 2021
Summary: Join us as we honor a group of 20 extraordinary women who are making lasting impacts in the drug development field.
View Now